The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1036
ISSUE1036
September 25, 1998
New Monoclonal Antibodies to Prevent Transplant Rejection
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
New Monoclonal Antibodies to Prevent Transplant Rejection
September 25, 1998 (Issue: 1036)
Basiliximab (Simulect - Novartis) and daclizumab (Zenapax - Roche), two mouse/human monoclonal antibodies that block the interleukin-2 (IL-2) receptor on Tlymphocytes, have been approved by the FDA for use in the prevention of acute renal ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.